EUVIMEDEUVIMED entdecken
Crossref

Assessing the therapeutic potential of astaxanthin in experimental proliferative vitreoretinopathy models

Hakan Veli Savaş iD, Hakan Yildirim iD, Nevin Ilhan iD, Yesari Eröksüz iD, Murat Erdağ iD, Mehmet Canleblebici iD, Mehmet Balbaba iD

European Journal of Ophthalmology · 2025

DOI: 10.1177/11206721251343166 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Ophthalmology, 2025. Verfasst von Hakan Veli Savaş und 6 weiteren Autor:innen. Beteiligte Einrichtung: Karakoçan State Hospital Eye Clinic, Elazığ, Turkey. Hauptthemen laut MEDLINE: Vitreoretinopathy, Proliferative, Disease Models, Animal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study evaluates the effectiveness of astaxanthin in treating experimental proliferative vitreoretinopathy (PVR) in rats.

Methods

Fifty-six Sprague Dawley rats were divided into 4 groups. PVR was induced using dispase and astaxanthin was administered intravitreally at concentrations of 10 ng/μL and 100 ng/μL. The effects on TGF-ß, VEGF, PDGF, FGF2 and IL-1ß were measured by ELISA and retinal changes were analysed histopathologically and immunohistochemically.

Results

Astaxanthin at 10 ng/μL and 100 ng/μL administered to the treatment groups significantly decreased TGF-β, VEGF, FGF2, IL-1, and PDGF levels compared to the sham group ( p < 0.05). At the 100 ng/μL dose, more significant decreases were observed, especially in PDGF and IL-1 levels ( p < 0.01). Histopathologic scoring revealed that the treated groups had significantly lower PVR scores than the Sham group, with the highest dose showing the greatest improvement ( p < 0.01). Furthermore, treated groups exhibited improved retinal architecture and reduced fibrotic tissue formation. Immunohistochemical staining for VEGF was positive in all groups except Control, with no significant differences in VEGF expression intensity between groups.

Conclusion

Astaxanthin effectively reduces both biochemical and histopathological markers of PVR, highlighting its potential as a novel therapeutic agent for managing this challenging condition in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vitreoretinopathy, ProliferativeDisease Models, AnimalAnimalsXanthophyllsRatsRats, Sprague-DawleyEnzyme-Linked Immunosorbent AssayIntravitreal InjectionsImmunohistochemistryVascular Endothelial Growth Factor AMaleRetinaPlatelet-Derived Growth Factor

Stichwörter der Autor:innen

Astaxanthinexperimental modelgrowth factorsproliferative vitreoretinopathy

Substanzen

astaxanthineXanthophyllsVascular Endothelial Growth Factor APlatelet-Derived Growth Factor

Autor:innen und Institutionen

  • Karakoçan State Hospital Eye Clinic, Elazığ, Turkey.
  • Fırat University Eye Clinic, Elazığ, Turkey.
  • Fırat University, Elazığ, Turkey.
  • Kayseri State Hospital Eye Clinic, Kayseri, Turkey.

ORCID-Profile: Hakan Veli Savaş, Hakan Yildirim, Nevin Ilhan, Yesari Eröksüz, Murat Erdağ, Mehmet Canleblebici, Mehmet Balbaba

Zitieren

APA

Savaş, H. V., Yildirim, H., Ilhan, N., Eröksüz, Y., Erdağ, M., Canleblebici, M., & Balbaba, M. (2025). Assessing the therapeutic potential of astaxanthin in experimental proliferative vitreoretinopathy models. European Journal of Ophthalmology. https://doi.org/10.1177/11206721251343166

Vancouver

Savaş HV, Yildirim H, Ilhan N, Eröksüz Y, Erdağ M, Canleblebici M, et al. Assessing the therapeutic potential of astaxanthin in experimental proliferative vitreoretinopathy models. European Journal of Ophthalmology. 2025. doi:10.1177/11206721251343166

BibTeX
@article{Sava2025,
  author = {Savaş, Hakan Veli and Yildirim, Hakan and Ilhan, Nevin and Eröksüz, Yesari and Erdağ, Murat and Canleblebici, Mehmet and Balbaba, Mehmet},
  title = {Assessing the therapeutic potential of astaxanthin in experimental proliferative vitreoretinopathy models},
  journal = {European Journal of Ophthalmology},
  year = {2025},
  doi = {10.1177/11206721251343166}
}
Kostenlos starten →